Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

Oxazepam

Oxazepam molecule structureOxazepam molecule structure
7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one
Serax, Serepax, Seresta, Sobril, Alepam

Oxazepam is an intermediate-acting benzodiazepine1 prescribed for the treatment of anxiety disorders2, panic disorders, alcohol withdrawalcitation needed, and insomnia1. It is characterized by relatively low potency compared to other benzodiazepines, a slow onset of action, and a simple metabolic profile that makes it less susceptible to variability based on age or liver functioncitation needed. It is notably an active metabolite of both diazepam and temazepam. Higher doses may produce amnesia and lowered inhibitions.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~5 mg
Light5-10 mg
Moderate10-30 mg
Strong30-45 mg
Heavy45+ mg

Duration

Onset30-60 minutes
After Effects1-10 hours
Total4-6 hours
Half-life
6-9 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

The oxazepam experience is dominated by calm, physical relaxation, and relief from anxiety, with essentially no sensory alteration. As a slow-onset, relatively mild benzodiazepine, its effects build gradually and center on sedation and a dampening of emotional intensity rather than any recreational high. At higher doses, inhibitions loosen and memory of the period after ingestion becomes patchy or absent.

Physical

Muscle relaxation and a heavy, sedated body feeling are the primary physical effects, accompanied by suppression of spasms and seizures. Fatigue, motor impairment, muscle weakness, headaches, and, at high doses, slowed breathing have been reported.

Sedation

Sedation is central to the experience, shading into sleep induction at higher doses.

Uncomfortable

DizzinessHeadaches

Cognitive

The headspace is calm and emotionally muted, with slowed thinking, reduced anxiety, and lowered inhibitions. Confusion and anterograde amnesia become increasingly likely as the dose rises.

Suppressions

Cognitive effects are broadly suppressive, reflecting reduced signaling between neurons across the central nervous system.

Pharmacology

Pharmacodynamics

Oxazepam acts as a positive allosteric modulator of GABA-A receptors, binding at the benzodiazepine site located at the interface between the alpha and gamma subunits of the receptor. This binding potentiates the inhibitory effects of endogenous GABA in the central nervous system.3 Oxazepam also acts as an agonist at the translocator protein and has been shown to suppress cortisol levels.citation needed

Pharmacokinetics

Oxazepam is metabolized through a relatively simple pathway involving direct glucuronidation, without requiring hepatic oxidation.citation needed The S-enantiomer is glucuronidated by UGT2B15, while the R-enantiomer is processed by UGT2B7 and UGT1A9, yielding a single major inactive glucuronide conjugate. Oxazepam itself is an active metabolite formed during the breakdown of diazepam, nordazepam, and temazepam, and it undergoes very little additional biotransformation following absorption. The mean elimination half-life is approximately 8.2 hours, with a reported range of 6 to 9 hours.

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholGHB/GBLOpioidsTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

DXMKetamineMXE
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance develops with regular use, typically within 4-6 weeks of continuous administration. As with other benzodiazepines, habituation can lead to significantly elevated dose requirements compared to initial effective doses.
Cross Tolerance

Benzodiazepines, Other GABAergic depressants

Baseline Reset
Following prolonged use, gradual dose tapering under medical supervision is required rather than abrupt discontinuation. Complete tolerance reset timelines are not well-documented but extended abstinence periods are typically necessary.

Harm Potential

Addiction & Dependence

Psychological

Moderate

Oxazepam has documented abuse potential as a benzodiazepine, though its slow absorption and onset of action result in relatively lower abuse potential compared to faster-acting benzodiazepines such as temazepam, flunitrazepam, or triazolam.citation needed Misuse, defined as taking the drug to achieve a high or continuing use against medical advice, has been documented.

Physical

High

Physical dependence develops with regular use, even at standard dosages and after relatively short-term use.citation needed Withdrawal symptoms are similar to those seen with alcohol and barbiturate withdrawal, including abdominal and muscle cramps, seizures, depression, insomnia, sweating, tremors, nausea, vomiting, and potentially hallucinations. Withdrawal should be medically supervised with gradual dose reduction.

Toxicity

Respiratory

Respiratory depression may occur in overdose or when combined with other CNS depressants;4 at typical doses, significant respiratory effects are uncommon except in patients with pre-existing pulmonary conditions such as COPD or limited pulmonary reserve.

Cardiovascular

Hypotension may rarely occur during use; cardiovascular toxicity is occasionally observed in overdose situations.

Psychosis Risk

Paradoxical reactions including excitement, confusion, aggression, outbursts of anger, and restlessness may occur as side effects.citation needed Hallucinations have been reported primarily as a withdrawal symptom rather than during active use.

Seizure Risk

Oxazepam itself has anticonvulsant properties as a benzodiazepine. However, seizures are a significant risk during withdrawal, particularly after prolonged use or abrupt discontinuation.4 Some benzodiazepines may trigger seizures in individuals with epilepsy. Flumazenil administration in long-term users may also precipitate seizures.4

History & Culture

Oxazepam was patented in 1962 and received approval for medical use in 1964. The compound became one of the most commonly prescribed benzodiazepines in multiple countries during the late 20th century.

Legality

International

1961 Single Convention: oxazepam is not scheduled.

1971 Convention on Psychotropic Substances: Schedule IV.

1988 Convention: oxazepam is not listed in precursor Tables I or II.

By Country

Prescription6
United States flagUnited StatesPrescription only
Australia flagAustraliaPrescription only
Canada flagCanadaPrescription only
Germany flagGermanyPrescription only
New Zealand flagNew ZealandPrescription only
United Kingdom flagUnited KingdomPrescription only

References

Source Pages

  1. DrugBank
  2. DrugBank: Oxazepam Metabolite
  3. PsychonautWiki: Oxazepam
  4. TripSit Wiki: Uncommon Benzodiazepines
  5. Wikipedia

Citations

  1. Ravneet Singh, Preeti Patel, & Sara Abdijadid. (2025). Oxazepam. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK544349/12
  2. OXAZEPAM capsule, gelatin coated — DailyMed (FDA Label, setid a0d5a4c1). DailyMed / NLM (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43123
  3. Engin E. (January 12, 2023). GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.10609491
  4. Oxazepam Capsules – Prescribing Information (DailyMed setid 67f821fa). U.S. National Library of Medicine / DailyMed (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67f821fa-5663-4d69-82c9-5ee13a09f324123
  5. Wood, Jennifer M.. (12 April 2017). 11 Words That Will Win You Any Game of Scrabble. Mental Floss. https://www.mentalfloss.com/article/50090/10-words-will-win-you-any-game-scrabble1
  6. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, Schedule 4. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/latest/text1
  7. Government of Canada. (n.d.). Controlled Drugs and Substances Act — Schedule IV. Justice Laws Website. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95660.html1
  8. Controlled Drugs and Substances Act, Schedule IV; Benzodiazepines and Other Targeted Substances Regulations (SOR/2000-217), Schedule 1. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/SOR-2000-217/section-sched661316.html1
  9. Controlled Drugs and Substances Act, Schedule IV; Benzodiazepines and Other Targeted Substances Regulations (SOR/2000-217), Schedule 1. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/SOR-2000-217/index.html1
  10. Betäubungsmittelgesetz, Anlage III; Betäubungsmittel-Verschreibungsverordnung. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

19 August 2026

  1. Lyrea · Changed a word in Dosage & DurationRoutes 1 › Stages › Onset

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Oxazepam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.